去勢療法抗性攝護腺癌近期治療指引與藥物介紹

10.6666/ClinMed.201909_84(3).0101

張嘉哲；鍾立民

攝護腺癌（prostate cancer） ； 攝護腺癌藥物（prostate cancer drug treatment） ； 轉移性去勢療法抗性攝護腺癌（metastatic castration resistant prostate cancer, mCRPC）

臨床醫學月刊

84卷3期（2019 / 09 / 27）

613 - 622

繁體中文

攝護腺癌是男性中最常見的惡性腫瘤，也是癌症死亡的主要原因。由於近年的檢查及藥物的進步，使得對攝護腺癌有更佳的了解，而在治療去勢療法抗性攝護腺癌的藥物不斷的進步，此篇綜論主要介紹目前對去勢療法抗性的攝護腺癌近期治療指引與藥物。

1. 衛生福利部國民健康署民癌記登記。
2. Bahl, A,Oudard, S,Tombal, B(2013).Impact of cabazitaxel on 2-year survival and palliation of tumour-related pain in men with metastatic castration-resistant prostate cancer treated in the TROPIC trial.Ann Oncol,24,2402-2408.
3. Berthold, DR,Pond, GR,Soban, F(2008).Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study.J Clin Oncol,26,242-245.
4. de Bono, JS,Oudard, S,Ozguroglu, M(2010).Prednisone plus cabazitaxel ormito-xantrone for metastatic castration resistant prostate cancer progressing after docetaxel treatment: a ran domised open-label trial.Lancet,376,1147-1154.
5. de Bono, JS,Oudard, S,Ozguroglu, M(2010).Prednisone plus cabazitaxel or mito-xantrone for metastatic castration resistant prostate cancer progressingafter docetaxel treatment: a randomised open-label trial.Lancet,376,1147-1154.
6. Eisenberger, M,Hardy-Bessard, AC,Kim, CS(2017).Phase III study comparing a reduced dose of cabazitaxel (20 mg/m(2)) and the currently approved dose (25 mg/m(2)) in postdocetaxel patients with metastatic castration-resistant prostate cancer-PROSELICA.J Clin Oncol,35,3198-3206.
7. Fizazi, K,Carducci, M,Smith, M(2011).Denosumab versus zoledronic acid fortreat-ment of bone metastases in men with castrationresistant prostate cancer: a random-ised, double-blind study.Lancet,377,813-822.
8. Fizazi, K,Faivre, L,Lesaunier, F(2015).Androgen deprivation therapy plus docetaxel and estramustine versus androgen deprivation therapy alone for high-risk localised prostate cancer (GETUG 12): a phase 3 randomised controlled trial.Lancet Oncol,16,787-794.
9. Fizazi, K,Scher, HI,Miller, K(2014).Effect of enzalutamide on time to first skeletal-related event, pain, and quality of life in men with castration-resistant prostatecancer: results from the randomised, phase 3 AFFIRM trial.Lancet Oncol,15,1147-1156.
10. Fizazi, K,Scher, HI,Molina, A(2012).Abiraterone acetate for treatment of metastatic castra tion-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, dou bleblind, placebo-controlled phase 3 study.Lancet Oncol,13,983-992.
11. Horwitz, EM,Bae, K,Hanks, GE(2008).Ten-year follow-up of radiation therapy on-cology group proto col 92-02: a phase III trial of the duration of elective androgen deprivation in locally advanced pros tate cancer.J Clin Oncol,26,2497-2504.
12. Hussain, M,Fizazi, K,Saad, F(2018).Enzalutamide in men with nonmetastatic, castra-tion-resistant prostate cancer.N Engl J Med,378,2465-2474.
13. James, ND,Sydes, MR,Clarke, NW(2016).Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): sur-vival results from an adaptive, multiarm, multistage, platform randomised controlled trial.Lancet,387,1163-1177.
14. James, ND,Sydes, MR,Clarke, NW(2016).Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): sur-vival results from an adaptive, multiarm, multistage, platformrandomised controlled trial.Lancet,387,1163-1177.
15. Kantoff, PW,Higano, CS,Shore, ND(2010).Sipuleucel-T immunotherapy for castration-resistant prostate cancer.N EnglJ Med,363,411-422.
16. Kellokumpu-Lehtinen, PL,Harmenberg, U,Joensuu, T(2013).Weekly versus 3-weekly docetaxel to treat castration resistant advanced prostate cancer: a random-ised, phase 3 trial.Lancet Oncol,14,117-124.
17. Kyriakopoulos, CE,Chen, YH,Carducci, MA(2018).Chemohormonal therapy in met-astatic hor mone-sensitive prostate cancer: Long-term survival analysis of the ran-domized phase III E3805 CHAARTED trial.J Clin Oncol,36,1080-1087.
18. Logothetis, CJ,Basch, E,Molina, A(2012).Effect of abiraterone acetate and predni-sone compared with placebo and prednisone on pain control and skeletal related events in patients with meta static castrationresistant prostate cancer: exploratory analysis of data from the COU-AA-301 ran domised trial.Lancet Oncol,13,1210-1217.
19. Marugame, T,Katanoda, K(2006).International comparisons of cumulative risk of breast and prostate can cer, from cancer incidence in fi ve continents Vol VIII.Jpn J Clin Oncol,36,399-400.
20. Package Insert(2017).Package Insert. KEYTRUDA ® (pembrolizumab). Whitehouse Station, NJ: Merck & Co, Inc. 2017..
21. Parker, C,Nilsson, S,Heinrich, D(2013).Alpha emitter radium-223 and survival in metastatic prostate cancer.N Engl J Med,369,213-223.
22. Penson, DF,Armstrong, AJ,Concepcion, R(2016).Enzalutamide versus bicalutamide in castra tion-resistant prostate cancer: the STRIVE trial.J Clin Oncol,34,2098-2106.
23. Petrylak, DP,Tangen, CM,Hussain, MH(2004).Docetaxel and estramustine compared with mitoxan trone and prednisone for advanced refractory prostate cancer.N Engl J Med,351,1513-1520.
24. Ryan, CJ,Smith, MR,de Bono, JS(2013).Abiraterone in metastatic prostate cancer without previous chemotherapy.N Engl J Med,368,138-148.
25. Ryan, CJ,Smith, MR,Fizazi, K(2015).Abiraterone acetate plus prednisone versus pla-cebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebocontrolled phase 3 study.Lancet Oncol,16,152-160.
26. Saad, F,Carles, J,Gillessen, S(2016).Radium-223 and concomitant therapies in pa-tients with meta static castration-resistant prostate cancer: an international, early ac-cess, open-label, single-arm phase 3b trial.Lancet Oncol,17,1306-1316.
27. Saad, F,Gleason, DM,Murray, R(2002).A randomized, placebocontrolled trial of zoledronic acid in patients with hormone refractory metastatic prostate carcinoma.J Natl Cancer Inst,94,1458-1468.
28. Sartor, O,Vogelzang, NJ,Sweeney, C(2018).Radium-223 safety, efficacy, and concur-rent use with abi raterone or enzalutamide: First U.S. Experience from an expanded access program.Oncologist,23,193-202.
29. Scher, HI,Fizazi, K,Saad, F(2012).Increased survival with enzalutamide in prostate cancer after chem otherapy.N Engl J Med,367,1187-1197.
30. Shore, ND,Chowdhury, S,Villers, A(2016).Efficacy and safety of enzalutamide ver-sus bicalutamide for patients with metastatic prostate cancer (TERRAIN): a ran-domised, double-blind, phase 2 study.Lancet Oncol,17,153-163.
31. Smith, MR,Saad, F,Chowdhury, S(2018).Apalutamide treatment and metastasis free survival in pros tate cancer.N Engl J Med,378,1408-1418.
32. Sweeney, CJ,Chen, YH,Carducci, M(2015).Chemohormonal therapy in metastatic hormone-sensitive prostate cancer.N Engl J Med,373,737-746.
33. Tannock, IF,Wit, R,Berry, WR(2004).Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer.N Engl J Med,351,1502-1512.